What is the primary target and objective of ENDEAVORRIDE?

It is designed as a digital therapeutics prescription app to assist in the treatment of pediatric Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged 6 to 17.

What were the specific clinical trial results that demonstrated the app's efficacy?

In a Phase 3 clinical trial conducted in Japan with 164 patients, the ENDEAVORRIDE group showed statistically significant improvement (p < 0.05) in the ADHD-RS-IV inattention score compared to the standard care group at week 6.

How does the app's core technology work to improve ADHD symptoms?

Based on the Akili Selective Stimulus Management Engine (SSME) core technology, it is designed to activate the prefrontal cortex by delivering personalized, adaptive dual-tasks that stimulate the cerebral cortex.

What is Akili's background and the regulatory status of the equivalent product in the US?

Akili, Inc., based in Washington, US, developed the technology. It previously received FDA approval for the world's first digital therapeutic for ADHD in pediatric patients (marketed as EndeavorRx in the US).

When were the license agreement and Japanese regulatory approval obtained?

The licensing agreement with Akili was signed on March 7, 2019, and the manufacturing and marketing approval in Japan was granted on February 18, 2025.

AI News NQ Analysis

Shionogi Launches 'ENDEAVORRIDE®' ADHD Digital Treatment App in Japan

Q: How does the app's core technology work to improve ADHD symptoms?

Based on the Akili Selective Stimulus Management Engine (SSME) core technology, it is designed to activate the prefrontal cortex by delivering personalized, adaptive dual-tasks that stimulate the cerebral cortex.

Q: What is Akili's background and the regulatory status of the equivalent product in the US?

Akili, Inc., based in Washington, US, developed the technology. It previously received FDA approval for the world's first digital therapeutic for ADHD in pediatric patients (marketed as EndeavorRx in the US).

Q: When were the license agreement and Japanese regulatory approval obtained?

The licensing agreement with Akili was signed on March 7, 2019, and the manufacturing and marketing approval in Japan was granted on February 18, 2025.

NQ Score 89/100

N1 Content Completeness 95

Key facts

Shionogi Launches 'ENDEAVORRIDE®' ADHD Digital Treatment App in Japan
Shionogi & Co., Ltd. has launched ENDEAVORRIDE®, Japan's first approved digital treatment app for pediatric ADHD, developed by Akili, Inc., to improve inattention, hyperactivity, and impulsivity.
Source: PR TIMES
Date: Fri Jun 05 2026 19:59:48 GMT+0900 (Japan Standard Time)

Direct answer

Shionogi & Co., Ltd. has launched ENDEAVORRIDE®, Japan's first approved digital treatment app for pediatric ADHD, developed by Akili, Inc., to improve inattention, hyperactivity, and impulsivity.

Citation: Shionogi Launches 'ENDEAVORRIDE®' ADHD Digital Treatment App in Japan (Fri Jun 05 2026 19:59:48 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Fri Jun 05 2026 19:59:48 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

Shionogi & Co., Ltd. has launched ENDEAVORRIDE®, Japan's first approved digital treatment app for pediatric ADHD, developed by Akili, Inc., to improve inattention, hyperactivity, and impulsivity.

AI Analysis

Frequently Asked Questions

Q: What is the primary target and objective of ENDEAVORRIDE?: A: It is designed as a digital therapeutics prescription app to assist in the treatment of pediatric Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged 6 to 17.
Q: What were the specific clinical trial results that demonstrated the app's efficacy?: A: In a Phase 3 clinical trial conducted in Japan with 164 patients, the ENDEAVORRIDE group showed statistically significant improvement (p < 0.05) in the ADHD-RS-IV inattention score compared to the standard care group at week 6.
Q: How does the app's core technology work to improve ADHD symptoms?: A: Based on the Akili Selective Stimulus Management Engine (SSME) core technology, it is designed to activate the prefrontal cortex by delivering personalized, adaptive dual-tasks that stimulate the cerebral cortex.
Q: What is Akili's background and the regulatory status of the equivalent product in the US?: A: Akili, Inc., based in Washington, US, developed the technology. It previously received FDA approval for the world's first digital therapeutic for ADHD in pediatric patients (marketed as EndeavorRx in the US).
Q: When were the license agreement and Japanese regulatory approval obtained?: A: The licensing agreement with Akili was signed on March 7, 2019, and the manufacturing and marketing approval in Japan was granted on February 18, 2025.